ABSTRACT
Coagulopathy is a frequent complication of patients with extensive Klippel-Trenaunay syndrome (KTS). High awareness and venous thromboembolism (VTE) prevention should be a priority in the care of these patients. Anticoagulation and antiplatelet management can be individualized using low-molecular-weight heparin and aspirin. The role of new anticoagulants in the management of KTS is unclear at this time.
